株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:大鬱病性障害 - 世界における医薬品の予測と市場分析

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 314723
出版日 ページ情報 英文 322 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
PharmaPoint:大鬱病性障害 - 世界における医薬品の予測と市場分析 PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023
出版日: 2014年05月31日 ページ情報: 英文 322 Pages
概要

大鬱病性障害(MDD)は、世界で最も一般的な精神疾患の1つです。MDD市場は競争が激しく、30以上もの上市製品がMDD患者の治療に使用可能です。鬱病市場では、主力製品(Eli LillyのCymbalta、大塚製薬/BMSのAbilify)の特許切れが差し迫り、抗鬱薬の新製品(Lundbeck/武田薬品工業のBrintellix)や将来有望な後期段階のパイプライン製品の導入を目前に、市場は大きく動いています。

当レポートでは、世界における大鬱病性障害(MDD)市場について調査分析し、疾患の概要とガイドライン、競合情勢、主要薬剤の詳細情報(製品説明、安全性、有効性)、SWOT分析、売上高予測、影響分析(動向、促進要因・抑制要因)などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 分類
  • 症状とサブタイプ
  • 予後
  • QOL

第4章 疫学

  • 危険因子と併存疾患
    • MDDの家族歴は約14倍のMDDリスク
    • 薬物乱用や生涯の不安障害はMDD患者に高度に蔓延
  • 世界的・歴史的な動向
  • 予測手法
    • 利用した情報源
    • 予測の前提条件と手法
    • 利用しなかった情報源
  • MDDの疫学予測
    • 有病者数
    • 有病者数:年齢別
    • 有病者数:性別
    • 有病率:年齢標準化
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第5章 疾患の管理

  • 診断と治療の概要
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • オーストラリア

第6章 競合評価

  • 概要
  • 製品プロファイル:主要ブランド、選択的セロトニン再取り込み阻害薬
  • 製品プロファイル:主要ブランド、セロトニン・ノルアドレナリン再取り込み阻害薬
  • 製品プロファイル:主要ブランド、その他の抗鬱薬
  • 製品プロファイル:主要ブランド、抗精神病薬
  • その他の治療薬クラス

第7章 機会とアンメットニーズ

  • 概要
  • 効果的な薬物療法
  • 好ましい副作用プロファイル
  • 抗鬱作用の迅速な発現
  • 個別化医療のアプローチ

第8章 パイプライン評価

  • 概要
  • 治験マッピング
  • 臨床開発中の有望な薬剤
  • その他の開発中の薬剤

第9章 現在/将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル

第10章 市場の見通し

  • 世界
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • オーストラリア

第11章 付録

図表

目次

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Highlights

Key Questions Answered

  • What will be the impact of imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta and Otsuka/BMS's Abilify in the MDD market
  • What do physicians think about Lundbeck/Takeda's Brintellix and what will be the impact of its 2014 launch in the MDD market
  • What is the significance of late-phase pipeline products and how will their launch shape the future treatment landscape in MDD
  • What are the significant unmet needs in the MDD market
  • What are the remaining opportunities in the MDD market

Key Findings

  • Minimal growth in the MDD market is expected from 2013 to 2023. The key drivers will be the increasing uptake for Lundbeck/Takeda's Brintellix, the potential introduction of seven late-stage pipeline drugs into the MDD market, and the increasing number of prevalent cases of MDD.
  • Key players develop products to broaden and strengthen their portfolios, enter into partnerships for the co-development and co-marketing of products in different regions, and develop products with a novel mechanism of action in order to compete effectively in the crowded depression market.
  • The most pressing unmet need in the depression market is for the development of drugs with improved efficacy.
  • Opportunities remain for products that will meet the significant unmet needs that exist in the MDD market. Products that demonstrate better efficacy, improved safety, and rapid antidepressant effects will move to the forefront of the treatment line.

Scope

  • Overview of MDD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
  • Annualized MDD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the MDD therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-stage pipeline drugs.
  • Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global MDD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MDD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global MDD therapeutics market from 2013-2023.
  • Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms and Subtypes of Major Depressive Disorder
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Risk Factors and Comorbidities
    • 4.1.1. A Family History of MDD Increases the Risk for MDD by Almost 14 Times
    • 4.1.2. Substance Abuse and Lifetime Anxiety Disorders are Highly Prevalent in MDD Patients
  • 4.2. Global and Historical Trends
  • 4.3. Forecast Methodology
    • 4.3.1. Sources Used
    • 4.3.2. Forecast Assumptions and Methods
    • 4.3.3. Sources Not Used
  • 4.4. Epidemiological Forecast for MDD (2013-2023)
    • 4.4.1. Total Prevalent Cases of MDD
    • 4.4.2. Age-Specific Total Prevalent Cases of MDD
    • 4.4.3. Sex-Specific Total Prevalent Cases of MDD
    • 4.4.4. Age-Standardized Total Prevalence of MDD
  • 4.5. Discussion
    • 4.5.1. Epidemiological Forecast Insight
    • 4.5.2. Limitations of the Analysis
    • 4.5.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. France
  • 5.4. Germany
  • 5.5. Italy
  • 5.6. Spain
  • 5.7. UK
  • 5.8. Japan
  • 5.9. Australia

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles: Major Brands, Selective Serotonin Reuptake Inhibitors
    • 6.2.1. Lexapro (Escitalopram)
    • 6.2.2. Viibryd (Vilazodone)
    • 6.2.3. Other Selective Serotonin Reuptake Inhibitors
  • 6.3. Product Profiles: Major Brands, Serotonin-Norepinephrine Reuptake Inhibitors
    • 6.3.1. Effexor (Venlafaxine)
    • 6.3.2. Cymbalta (Duloxetine)
    • 6.3.3. Pristiq (Desvenlafaxine)
    • 6.3.4. Fetzima (Levomilnacipran)
    • 6.3.5. Savella (Milnacipran)
  • 6.4. Product Profiles: Major Brands, Other Antidepressants
    • 6.4.1. Norepinephrine-Dopamine Reuptake Inhibitors
    • 6.4.2. Noradrenaline and Specific Serotonergic Antidepressants
    • 6.4.3. Monoamine Oxidase Inhibitors
    • 6.4.4. Tricyclic Antidepressants
    • 6.4.5. Brintellix (Vortioxetine)
  • 6.5. Product Profiles: Major Brands, Antipsychotics
    • 6.5.1. Abilify (Aripiprazole)
    • 6.5.2. Seroquel XR (Quetiapine)
  • 6.6. Other Therapeutic Classes

7. Unmet Needs and Opportunities

  • 7.1. Overview
  • 7.2. More Effective Pharmacotherapies
    • 7.2.1. Unmet Needs
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunities
  • 7.3. More Favorable Side Effect Profiles
    • 7.3.1. Unmet Needs
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunities
  • 7.4. Rapid Onset of Antidepressant Effects
    • 7.4.1. Unmet Needs
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunities
  • 7.5. Personalized Treatment Approach
    • 7.5.1. Unmet Needs
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunities

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Class of Therapy
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Brexpiprazole (OPC-34712)
    • 8.3.2. Cariprazine (RGH-188)
    • 8.3.3. ALKS-5461
    • 8.3.4. Amitifadine (EB-1010)
    • 8.3.5. GLYX-13
    • 8.3.6. Tedatioxetine (Lu AA24530)
    • 8.3.7. ETS6103
  • 8.4. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Lundbeck
    • 9.3.2. Forest Laboratories (Actavis)
    • 9.3.3. Eli Lilly
    • 9.3.4. Pfizer
    • 9.3.5. Otsuka Pharmaceutical
    • 9.3.6. AstraZeneca
    • 9.3.7. Takeda Pharmaceutical
    • 9.3.8. Alkermes
    • 9.3.9. Euthymics Bioscience
    • 9.3.10. Naurex
    • 9.3.11. e-Therapeutics

10. Market Outlook

  • 10.1. Global
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. UK
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. Australia
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed MDD Patients
    • 11.4.2. Percent of Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in this Study
  • 11.6. About the Authors
    • 11.6.1. Analyst
    • 11.6.2. Therapy Area Directors
    • 11.6.3. Epidemiologist
    • 11.6.4. Global Head of Healthcare
  • 11.7. About GlobalData
  • 11.8. Disclaimer

List of Tables

  • Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10)
  • Table 2: Subtypes of Major Depressive Disorder
  • Table 3: Risk Factors and Comorbidities for MDD
  • Table 4: Prevalence of the Most Frequent Psychiatric Comorbidities in Individuals with and without MDD
  • Table 5: Total Prevalence (%) of MDD According to the DSM-IV Criteria
  • Table 6: Total Prevalence* (%) of MDD According to the DSM-III Criteria
  • Table 7: Sources of the MDD Prevalence Data Used to Forecast the Total Prevalent Cases of MDD
  • Table 8: Sources Excluded from the Forecast for the Total Prevalent Cases of MDD
  • Table 9: Total Prevalent Cases of MDD, Ages ≥20 Years, Both Sexes, N, 2013-2023
  • Table 10: Total Prevalent Cases of MDD, by Age, Both Sexes, N (Row %), 2013
  • Table 11: Total Prevalent Cases of MDD, by Sex, Ages ≥20 Years, N (Row %), 2013
  • Table 12: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria
  • Table 13: Treatment Guidelines for Major Depressive Disorder
  • Table 14: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 2013
  • Table 15: Country Profile - US
  • Table 16: Country Profile - France
  • Table 17: Country Profile - Germany
  • Table 18: Country Profile - Italy
  • Table 19: Country Profile - Spain
  • Table 20: Country Profile - UK
  • Table 21: Country Profile - Japan
  • Table 22: Country Profile - Australia
  • Table 23: Leading Treatments for MDD, 2013
  • Table 24: Product Profile - Lexapro
  • Table 25: Safety of Lexapro - Five Most Frequently Reported Adverse Events
  • Table 26: Lexapro SWOT Analysis, 2014
  • Table 27: Global MDD Sales Forecasts ($m) for Lexapro, 2013-2023
  • Table 28: Product Profile - Viibryd
  • Table 29: Summary of Efficacy Results for the Primary Endpoint in Viibryd Clinical Trials
  • Table 30: Safety of Viibryd - Five Most Frequently Reported Adverse Events
  • Table 31: Viibryd SWOT Analysis, 2023
  • Table 32: Global MDD Sales Forecasts ($m) for Viibryd, 2013-2023
  • Table 33: Relative Frequency of Common Adverse Effects for Different SSRIs
  • Table 34: Global MDD Sales Forecasts ($m) for Other SSRIs, 2013-2023
  • Table 35: Product Profile - Effexor
  • Table 36: Effexor SWOT Analysis, 2014
  • Table 37: Global MDD Sales Forecasts ($m) for Effexor XR, 2013-2023
  • Table 38: Product Profile - Cymbalta
  • Table 39: Cymbalta SWOT Analysis, 2023
  • Table 40: Global MDD Sales Forecasts ($m) for Cymbalta, 2013-2023
  • Table 41: Product Profile - Pristiq
  • Table 42: Efficacy of Pristiq in short-term studies
  • Table 43: Pristiq SWOT Analysis, 2014
  • Table 44: Global MDD Sales Forecasts ($m) for Pristiq, 2013-2023
  • Table 45: Product Profile - Fetzima
  • Table 46: Clinical Efficacy of Fetzima from its Three Pivotal Studies
  • Table 47: Safety of Fetzima - Five Most Frequently Reported Adverse Events in Clinical Studies
  • Table 48: Fetzima SWOT Analysis, 2014
  • Table 49: Global MDD Sales Forecasts ($m) for Fetzima, 2013-2023
  • Table 50: Product Profile - Savella
  • Table 51: Savella SWOT Analysis, 2014
  • Table 52: Global Sales Forecasts ($m) for Savella, 2013-2023
  • Table 53: Product Profile - Bupropion
  • Table 54: Safety of Bupropion - Five Most Frequently Reported Adverse Events
  • Table 55: Bupropion SWOT Analysis, 2014
  • Table 56: Global MDD Sales Forecasts ($m) for Bupropion 2013-2023
  • Table 57: Product Profile - Mirtazapine
  • Table 58: Safety of Mirtazapine - Four Most Frequently Reported Adverse Events
  • Table 59: Mirtazapine SWOT Analysis, 2014
  • Table 60: Global MDD Sales Forecasts ($m) for Mirtazapine, 2013-2023
  • Table 61: MAOI SWOT Analysis, 2014
  • Table 62: Global MDD Sales Forecasts ($m) for MAOIs, 2013-2023
  • Table 63: TCAs SWOT Analysis, 2014
  • Table 64: Global MDD Sales Forecasts ($m) for TCAs, 2013-2023
  • Table 65: Product Profile - Brintellix
  • Table 66: Efficacy of Brintellix in Six-Week to Eight-Week Clinical Trials
  • Table 67: Safety of Brintellix - Five Most Frequently Reported Adverse Events
  • Table 68: Brintellix SWOT Analysis, 2014
  • Table 69: Global MDD Sales Forecasts ($m) for Brintellix, 2013-2023
  • Table 70: Product Profile - Abilify
  • Table 71: Safety of Abilify - Five Most Frequently Reported Adverse Events
  • Table 72: Abilify SWOT Analysis, 2014
  • Table 73: Global MDD Sales Forecasts ($m) for Abilify, 2013-2023
  • Table 74: Product Profile - Seroquel XR
  • Table 75: Efficacy of Seroquel XR as an Adjunctive Therapy to Antidepressants
  • Table 76: Safety of Seroquel XR- Five Most Frequently Reported Adverse Events
  • Table 77: Seroquel XR SWOT Analysis, 2014
  • Table 78: Global MDD Sales Forecasts ($m) for Seroquel XR, 2013-2023
  • Table 79: Summary of Minor Therapeutic Classes in MDD, 2013
  • Table 80: Unmet Needs and Opportunities in MDD
  • Table 81: Comparison of Therapeutic Classes in Development for MDD, 2013
  • Table 82: Product Profile - Brexpiprazole
  • Table 83: Safety of Brexpiprazole - Most Frequently Reported Adverse Events
  • Table 84: Brexpiprazole SWOT Analysis, 2014
  • Table 85: Global MDD Sales Forecasts ($m) for Brexpiprazole, 2013-2023
  • Table 86: Product Profile - Cariprazine
  • Table 87: Cariprazine SWOT Analysis, 2014
  • Table 88: Global MDD Sales Forecasts ($m) for Cariprazine, 2013-2023
  • Table 89: Product Profile - ALKS-5461
  • Table 90: ALKS-5461 SWOT Analysis, 2014
  • Table 91: Global MDD Sales Forecasts ($m) for ALKS-5461, 2013-2023
  • Table 92: Product Profile - Amitifadine
  • Table 93: Amitifadine SWOT Analysis, 2014
  • Table 94: Global MDD Sales Forecasts ($m) for Amitifadine, 2013-2023
  • Table 95: Product Profile - GLYX-13
  • Table 96: GLYX-13 SWOT Analysis, 2014
  • Table 97: Global MDD Sales Forecasts ($m) for GLYX-13, 2013-2023
  • Table 98: Product Profile - Tedatioxetine
  • Table 99: Tedatioxetine SWOT Analysis, 2014
  • Table 100: Global MDD Sales Forecasts ($m) for Tedatioxetine, 2013-2023
  • Table 101: Product Profile - ETS6103
  • Table 102: ETS6103 SWOT Analysis, 2014
  • Table 103: Global MDD Sales Forecasts ($m) for ETS6103, 2013-2023
  • Table 104: Drugs in Development for MDD, 2014
  • Table 105: Key Companies in the MDD Market in the 7MM and Australia, 2013
  • Table 106: Lundbeck's MDD Portfolio Assessment, 2013
  • Table 107: Forest (Actavis)'s MDD Portfolio Assessment, 2013
  • Table 108: Eli Lilly's MDD Portfolio Assessment, 2013
  • Table 109: Pfizer's MDD Portfolio Assessment, 2013
  • Table 110: Otsuka's MDD Portfolio Assessment, 2013
  • Table 111: AstraZeneca's MDD Portfolio Assessment, 2013
  • Table 112: Takeda's MDD Portfolio Assessment, 2013
  • Table 113: Alkermes's MDD Portfolio Assessment, 2013
  • Table 114: Euthymics Bioscience's MDD Portfolio Assessment, 2013
  • Table 115: Naurex's MDD Portfolio Assessment, 2013
  • Table 116: e-Therapeutics's MDD Portfolio Assessment, 2013
  • Table 117: Global Sales Forecasts ($) for MDD, 2013-2023
  • Table 118: MDD Market - Drivers and Barriers, 2013-2023
  • Table 119: Sales Forecasts ($m) for MDD in the US, 2013-2023
  • Table 120: Key Events Impacting Sales for MDD in the US, 2013-2023
  • Table 121: MDD Market in the US - Drivers and Barriers, 2013-2023
  • Table 122: Sales Forecasts ($m) for MDD in France, 2013-2023
  • Table 123: Key Events Impacting Sales for MDD in France, 2013-2023
  • Table 124: MDD Market in France - Drivers and Barriers, 2013-2023
  • Table 125: Sales Forecasts ($m) for MDD in Germany, 2013-2023
  • Table 126: Key Events Impacting Sales for MDD in Germany, 2013-2023
  • Table 127: MDD Market in Germany - Drivers and Barriers, 2013-2023
  • Table 128: Sales Forecasts ($m) for MDD in Italy, 2013-2023
  • Table 129: Key Events Impacting Sales for MDD in Italy, 2013-2023
  • Table 130: MDD Market in Italy - Drivers and Barriers, 2013-2023
  • Table 131: Sales Forecasts ($m) for MDD in Spain, 2013-2023
  • Table 132: Key Events Impacting Sales for MDD in Spain, 2013-2023
  • Table 133: MDD Market in Spain - Drivers and Barriers, 2013-2023
  • Table 134: Sales Forecasts ($m) for MDD in the UK, 2013-2023
  • Table 135: Key Events Impacting Sales for MDD in the UK, 2013-2023
  • Table 136: MDD Market in the UK - Drivers and Barriers, 2013-2023
  • Table 137: Sales Forecasts ($m) for MDD in Japan, 2013-2023
  • Table 138: Key Events Impacting Sales for MDD in Japan, 2013-2023
  • Table 139: MDD Market in Japan - Drivers and Barriers, 2013-2013
  • Table 140: Sales Forecasts ($m) for MDD in Australia, 2013-2023
  • Table 141: Key Events Impacting Sales for MDD in Australia, 2013-2023
  • Table 142: MDD Market in Australia - Drivers and Barriers, 2013-2023
  • Table 143: Key Launch Dates
  • Table 144: Key Patent Expiries
  • Table 145: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
  • Figure 2: Total Prevalent Cases of MDD, Ages ≥20 Years, Both Sexes, N, 2013-2023
  • Figure 3: Total Prevalent Cases of MDD, by Age, Both Sexes, N, 2013
  • Figure 4: Total Prevalent Cases of MDD, by Sex, Ages ≥20 Years, N, 2013
  • Figure 5: Age-Standardized Total Prevalence (%) of MDD, by Sex, Ages ≥20 Years, 2013
  • Figure 6: Disease Management Model for Major Depressive Disorder
  • Figure 7: Major Depressive Disorder Treatment Algorithm
  • Figure 8: Major Depressive Disorder Therapeutics - Class of Therapy, 2014
  • Figure 9: MDD - Phase IIb-III Pipeline, 2014
  • Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2013-2023
  • Figure 11: Clinical and Commercial Positioning of Brexpiprazole
  • Figure 12: Clinical and Commercial Positioning of Cariprazine
  • Figure 13: Clinical and Commercial Positioning of ALKS-5461
  • Figure 14: Clinical and Commercial Positioning of Amitifadine
  • Figure 15: Clinical and Commercial Positioning of GLYX-13
  • Figure 16: Clinical and Commercial Positioning of Tedatioxetine
  • Figure 17: Clinical and Commercial Positioning of ETS6103
  • Figure 18: Company Portfolio Gap Analysis in MDD, 2013-2023
  • Figure 19: Lundbeck SWOT Analysis in MDD, 2013-2023
  • Figure 20: Forest (Actavis) SWOT Analysis in MDD, 2013-2023
  • Figure 21: Eli Lilly SWOT Analysis in MDD, 2013-2023
  • Figure 22: Pfizer SWOT Analysis in MDD, 2013-2023
  • Figure 23: Otsuka SWOT Analysis in MDD, 2013-2023
  • Figure 24: AstraZeneca SWOT Analysis in MDD, 2013-2023
  • Figure 25: Takeda SWOT Analysis in MDD, 2013-2023
  • Figure 26: Alkermes SWOT Analysis in MDD, 2013-2023
  • Figure 27: Euthymics Bioscience SWOT Analysis in MDD, 2013-2023
  • Figure 28: Naurex SWOT Analysis in MDD, 2013-2023
  • Figure 29: e-Therapeutics SWOT Analysis in MDD, 2013-2023
  • Figure 30: Global Sales for MDD by Region, 2013-2023
  • Figure 31: Sales for MDD in the US by Drug Class, 2013-2023
  • Figure 32: Sales for MDD in France by Drug Class, 2013-2023
  • Figure 33: Sales for MDD in Germany by Drug Class, 2013-2023
  • Figure 34: Sales for MDD in Italy by Drug Class, 2013-2023
  • Figure 35: Sales for MDD in Spain by Drug Class, 2013-2023
  • Figure 36: Sales for MDD in the UK by Drug Class, 2013-2023
  • Figure 37: Sales for MDD in Japan by Drug Class, 2013-2023
  • Figure 38: Sales for MDD in Australia by Drug Class, 2013-2023
Back to Top